866-997-4948(US-Canada Toll Free)

Epithelial Ovarian Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : May 2016

Category :

Ovarian Cancer

No. of Pages : 479 Pages

Epithelial Ovarian Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Epithelial Ovarian Cancer - Pipeline Review, H1 2016, provides an overview of the Epithelial Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
- The report reviews pipeline therapeutics for Epithelial Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Epithelial Ovarian Cancer therapeutics and enlists all their major and minor projects
- The report assesses Epithelial Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
Introduction 6
Epithelial Ovarian Cancer Overview 7
Therapeutics Development 8
Epithelial Ovarian Cancer - Therapeutics under Development by Companies 10
Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 14
Epithelial Ovarian Cancer - Pipeline Products Glance 15
Epithelial Ovarian Cancer - Products under Development by Companies 18
Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 23
Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 24
Epithelial Ovarian Cancer - Therapeutics Assessment 86
Drug Profiles 102
Epithelial Ovarian Cancer - Recent Pipeline Updates 294
Epithelial Ovarian Cancer - Dormant Projects 456
Epithelial Ovarian Cancer - Discontinued Products 460
Epithelial Ovarian Cancer - Product Development Milestones 461
Appendix 468

List of Tables
Number of Products under Development for Epithelial Ovarian Cancer, H1 2016 18
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2016 19
Number of Products under Development by Companies, H1 2016 20
Number of Products under Development by Companies, H1 2016 (Contd..1) 21
Number of Products under Development by Companies, H1 2016 (Contd..2) 22
Number of Products under Development by Companies, H1 2016 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2016 24
Comparative Analysis by Late Stage Development, H1 2016 25
Comparative Analysis by Clinical Stage Development, H1 2016 26
Comparative Analysis by Early Stage Development, H1 2016 27
Products under Development by Companies, H1 2016 28
Products under Development by Companies, H1 2016 (Contd..1) 29
Products under Development by Companies, H1 2016 (Contd..2) 30
Products under Development by Companies, H1 2016 (Contd..3) 31
Products under Development by Companies, H1 2016 (Contd..4) 32
Products under Investigation by Universities/Institutes, H1 2016 33
Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H1 2016 34
Epithelial Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 35
Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H1 2016 36
Epithelial Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 37
Epithelial Ovarian Cancer - Pipeline by AstraZeneca Plc, H1 2016 38
Epithelial Ovarian Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016 39
Epithelial Ovarian Cancer - Pipeline by Bayer AG, H1 2016 40
Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2016 41
Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 42
Epithelial Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 43
Epithelial Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2016 44
Epithelial Ovarian Cancer - Pipeline by Celsion Corporation, H1 2016 45
Epithelial Ovarian Cancer - Pipeline by CerRx, Inc., H1 2016 46
Epithelial Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 47
Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H1 2016 48
Epithelial Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 49
Epithelial Ovarian Cancer - Pipeline by EirGenix Inc., H1 2016 50
Epithelial Ovarian Cancer - Pipeline by Eisai Co., Ltd., H1 2016 51
Epithelial Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2016 52
Epithelial Ovarian Cancer - Pipeline by Exelixis, Inc., H1 2016 53
Epithelial Ovarian Cancer - Pipeline by Genentech, Inc., H1 2016 54
Epithelial Ovarian Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016 55
Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H1 2016 56
Epithelial Ovarian Cancer - Pipeline by Ignyta, Inc., H1 2016 57
Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H1 2016 58
Epithelial Ovarian Cancer - Pipeline by Incyte Corporation, H1 2016 59
Epithelial Ovarian Cancer - Pipeline by Innate Immunotherapeutics Ltd, H1 2016 60
Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H1 2016 61
Epithelial Ovarian Cancer - Pipeline by Juno Therapeutics Inc., H1 2016 62
Epithelial Ovarian Cancer - Pipeline by Mabion SA, H1 2016 63
Epithelial Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 64
Epithelial Ovarian Cancer - Pipeline by MedImmune, LLC, H1 2016 65
Epithelial Ovarian Cancer - Pipeline by Merck & Co., Inc., H1 2016 66
Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 67
Epithelial Ovarian Cancer - Pipeline by Mycenax Biotech Inc., H1 2016 68
Epithelial Ovarian Cancer - Pipeline by Novartis AG, H1 2016 69
Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2016 70
Epithelial Ovarian Cancer - Pipeline by OBI Pharma, Inc., H1 2016 71
Epithelial Ovarian Cancer - Pipeline by Oncobiologics, Inc., H1 2016 72
Epithelial Ovarian Cancer - Pipeline by Oncolix, Inc., H1 2016 73
Epithelial Ovarian Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 74
Epithelial Ovarian Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 75
Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica Plc, H1 2016 76
Epithelial Ovarian Cancer - Pipeline by OXiGENE, Inc., H1 2016 77
Epithelial Ovarian Cancer - Pipeline by Pfizer Inc., H1 2016 78
Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H1 2016 79
Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 80
Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H1 2016 81
Epithelial Ovarian Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016 82
Epithelial Ovarian Cancer - Pipeline by Quest PharmaTech Inc., H1 2016 83
Epithelial Ovarian Cancer - Pipeline by Sanofi, H1 2016 84
Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H1 2016 85
Epithelial Ovarian Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 86
Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H1 2016 87
Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 88
Epithelial Ovarian Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 89
Epithelial Ovarian Cancer - Pipeline by Tesaro, Inc., H1 2016 90
Epithelial Ovarian Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2016 91
Epithelial Ovarian Cancer - Pipeline by Tyrogenex, Inc., H1 2016 92
Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016 93
Epithelial Ovarian Cancer - Pipeline by ViiV Healthcare Limited, H1 2016 94
Epithelial Ovarian Cancer - Pipeline by Vyriad, H1 2016 95
Assessment by Monotherapy Products, H1 2016 96
Number of Products by Stage and Target, H1 2016 98
Number of Products by Stage and Mechanism of Action, H1 2016 104
Number of Products by Stage and Route of Administration, H1 2016 109
Number of Products by Stage and Molecule Type, H1 2016 111
Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2016 304
Epithelial Ovarian Cancer - Dormant Projects, H1 2016 466
Epithelial Ovarian Cancer - Dormant Projects (Contd..1), H1 2016 467
Epithelial Ovarian Cancer - Dormant Projects (Contd..2), H1 2016 468
Epithelial Ovarian Cancer - Dormant Projects (Contd..3), H1 2016 469
Epithelial Ovarian Cancer - Discontinued Products, H1 2016 470

List of Figures
Number of Products under Development for Epithelial Ovarian Cancer, H1 2016 18
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2016 19
Number of Products under Development by Companies, H1 2016 20
Number of Products under Investigation by Universities/Institutes, H1 2016 24
Comparative Analysis by Late Stage Development, H1 2016 25
Comparative Analysis by Clinical Stage Development, H1 2016 26
Comparative Analysis by Early Stage Products, H1 2016 27
Assessment by Monotherapy Products, H1 2016 96
Number of Products by Top 10 Targets, H1 2016 97
Number of Products by Stage and Top 10 Targets, H1 2016 97
Number of Products by Top 10 Mechanism of Actions, H1 2016 103
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 103
Number of Products by Top 10 Routes of Administration, H1 2016 108
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 108
Number of Products by Top 10 Molecule Types, H1 2016 110
Number of Products by Stage and Top 10 Molecule Types, H1 2016 110

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *